Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAESTRO: Esomeprazole Strategies in GERD
NCT00444275Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of esomeprazole in gastroesophageal reflux disease (GERD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Efficacy of Three Strategies of Long-term Treatment at 16 weeks. Started Mar 2007; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00444275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00444275.